John Libbey Eurotext

L'Information Psychiatrique


Pharmacological management of schizophrenia with early and very early onset. Volume 94, issue 6, Juin-Juillet 2018


  • Figure 1
  • Figure 2
1 EPS de Ville-Évrard,
202 avenue Jean Jaurès
93332 Neuilly-sur-Marne, France
2 Assistante spécialiste
3 Praticien hospitalier chef du pôle 93I03
* Correspondant
  • Key words: child psychiatry, schizophrenia, adolescent, psychotic first episode, management, neuroleptic, intracranial magnetic stimulation
  • DOI : 10.1684/ipe.2018.1824
  • Page(s) : 445-50
  • Published in: 2018

Early Onset Schizophrenia (EOS, before 16-17 years) and Very Early-Onset Schizophrenia (VEOS, before 12-13 years) are severe and debilitating pathologies that require a global, multidisciplinary management, including an educational component. Regarding pharmacological choices, most of the prescriptions are off-label, the international recommendations are globally similar to those of adult schizophrenic disorders as they provide treatment with Clozapine in cases of resistance to two lines of antipsychotics. However, some authors recommend a rapid use of Clozapine after failure of first line treatment because of the superiority of this molecule compared to other antipsychotics in EOS and VEOS. Antipsychotics are less effective and less well tolerated in children and teenagers than in adults. Due to this poor tolerability, other therapeutic options are being explored such as rTMS and TDCS. However, more studies would be required to evaluate the efficacy and /or safety of these new treatment options in children and adolescents.